Advanced Biomed (NASDAQ:ADVB) Stock Gets Downgrade from Wall Street Zen

Advanced Biomed (NASDAQ:ADVB) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Advanced Biomed Price Performance

Shares of NASDAQ:ADVB opened at $3.99 on Friday. The company’s 50-day moving average price is $7.55 and its two-hundred day moving average price is $6.45. The stock has a market capitalization of $6.58 million, a PE ratio of 0.97 and a beta of 0.01. Advanced Biomed has a one year low of $3.61 and a one year high of $24.23.

Advanced Biomed (NASDAQ:ADVB) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $0.44 earnings per share for the quarter.

About Advanced Biomed

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.